MA42160A - Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii - Google Patents
Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type iiInfo
- Publication number
- MA42160A MA42160A MA042160A MA42160A MA42160A MA 42160 A MA42160 A MA 42160A MA 042160 A MA042160 A MA 042160A MA 42160 A MA42160 A MA 42160A MA 42160 A MA42160 A MA 42160A
- Authority
- MA
- Morocco
- Prior art keywords
- thalassemia
- cell culture
- beta
- receptor ligand
- vitro cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000005606 Activins Human genes 0.000 title abstract 2
- 108010059616 Activins Proteins 0.000 title abstract 2
- 239000000488 activin Substances 0.000 title abstract 2
- 208000005980 beta thalassemia Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 238000012606 in vitro cell culture Methods 0.000 title 1
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164367P | 2015-05-20 | 2015-05-20 | |
| US201662320032P | 2016-04-08 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42160A true MA42160A (fr) | 2018-03-28 |
Family
ID=57320751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042160A MA42160A (fr) | 2015-05-20 | 2016-05-19 | Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10548976B2 (enExample) |
| EP (2) | EP3298034A4 (enExample) |
| JP (2) | JP2018522579A (enExample) |
| CN (1) | CN108350057A (enExample) |
| CA (1) | CA2986432A1 (enExample) |
| HK (1) | HK1252174A1 (enExample) |
| MA (1) | MA42160A (enExample) |
| WO (1) | WO2016187378A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| CN110099995A (zh) * | 2017-01-06 | 2019-08-06 | 奥林巴斯株式会社 | 细胞观察系统 |
| CN111801112A (zh) * | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| PE20230783A1 (es) * | 2020-06-23 | 2023-05-11 | Acceleron Pharma Inc | Proteinas actrii para el tratamiento de la hipertension pulmonar |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022098877A1 (en) * | 2020-11-06 | 2022-05-12 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000046349A1 (en) | 1999-02-04 | 2000-08-10 | Technion Research & Development Foundation Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP1824796A4 (en) | 2004-11-16 | 2010-02-17 | Avidia Res Inst | PROTEIN SKELETONS AND USES THEREOF |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008076437A2 (en) | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| CN102655872B (zh) | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| JP6211767B2 (ja) | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| WO2011056896A1 (en) | 2009-11-03 | 2011-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| KR20140084211A (ko) * | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| CA2889286A1 (en) | 2012-10-24 | 2014-05-01 | Celgene Corporation | Methods for treating anemia |
| EP2912462B1 (en) | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP6976859B2 (ja) | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CN116531490A (zh) | 2016-07-15 | 2023-08-04 | 阿塞勒隆制药公司 | 用于治疗肺高血压的组合物和方法 |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| HUE068733T2 (hu) | 2017-06-14 | 2025-01-28 | Celgene Corp | Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére |
-
2016
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/en not_active Withdrawn
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/en not_active Ceased
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 HK HK18111575.0A patent/HK1252174A1/zh unknown
- 2016-05-19 CA CA2986432A patent/CA2986432A1/en active Pending
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/en not_active Withdrawn
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4190805A2 (en) | 2023-06-07 |
| EP3298034A4 (en) | 2019-02-13 |
| EP4190805A3 (en) | 2023-08-16 |
| CN108350057A (zh) | 2018-07-31 |
| WO2016187378A1 (en) | 2016-11-24 |
| US10548976B2 (en) | 2020-02-04 |
| EP3298034A1 (en) | 2018-03-28 |
| HK1252174A1 (zh) | 2019-05-17 |
| US20180161426A1 (en) | 2018-06-14 |
| CA2986432A1 (en) | 2016-11-24 |
| JP2018522579A (ja) | 2018-08-16 |
| US20200101157A1 (en) | 2020-04-02 |
| JP2022023072A (ja) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000099A1 (en) | Anti-lag-3 antibodies and compositions | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| SA520411982B1 (ar) | Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان | |
| MA50949B1 (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MX2021010025A (es) | Tratamiento de lesión renal. | |
| MA44659B1 (fr) | Anticorps anti-tim-3 et compositions | |
| MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA40132A1 (fr) | Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| MD4685B1 (ro) | Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA34002B1 (fr) | Thérapie antivirale | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
| EA202190073A1 (ru) | Композиции и способы лечения видов гемоглобинопатии и талассемии | |
| MA35638B1 (fr) | 2-thiopyrimidinones | |
| FR3045834B1 (fr) | Diluant de reactifs pour immunoessai | |
| MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| EP3386949A4 (en) | GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN | |
| EP4461314A3 (en) | Methods and materials for killing hiv infected cells | |
| FR3068045B1 (fr) | Modeles de peau sensible reconstituee | |
| EP4389221A3 (en) | Pan-genotypic agents against influenza virus and methods of using the same | |
| MA39355B2 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants |